ResearchMoz

Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth

GBI Research
Published Date » 2014-02-06
No. Of Pages » 76
   
 GBI Research has released its pharma report “Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 - CFTR Modulators Initiate Drive Towards Personalized Treatment and Market Growth.” The value of the Cystic Fibrosis (CF) market is expected to increase significantly in value over the forecast period across the leading eight developed nations, from $695.6 million in 2012 to almost $4.5 billion in 2019. This equates to a Compound Annual Growth Rate (CAGR) of 30.4%. Novel treatments with disease-modifying mechanisms of action are the primary factor driving the growth of the value of the market. The positive impact of new market entrants will offset the effects of key patent losses during the forecast period.  
   
 Cystic Fibrosis Transmembrane conductance...
TABLE OF CONTENT

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Symptoms
2.3 Etiology
2.4 Pathophysiology
2.5 Diagnosis
2.6 Prognosis
2.7 Assessment of Disease Severity
2.8 Treatment

3 Marketed Products
3.1 Overview
3.2 Product Profiles
3.2.1 Pulmozyme (dornase alfa) – Genentech
3.2.2 Bronchitol (mannitol) – Pharmaxis
3.2.3 TOBI (tobramycin) – Novartis
3.2.4 TOBI Podhaler (tobramycin) – Novartis
3.2.5 Bramitob/Bethkis (tobramycin) – Chiesi Farmaceutici
3.2.6 Colobreathe (colistimethate sodium) – Forest Laboratories
3.2.7 Cayston (aztreonam) – Gilead Sciences
3.2.8 Kalydeco (ivacaftor) – Vertex Pharmaceuticals
3.2.9 Pancreatic Enzyme Replacement Therapies
3.2.10 Other Successful Products
3.3 Heat Map of Marketed Products
3.4 Conclusion

4 Developmental Pipeline
4.1 Overview
4.2 Mechanisms of Action in the Pipeline
4.3 Clinical Trials
4.3.1 Failure Rate
4.3.2 Clinical Trial Duration
4.3.3 Clinical Trial Size
4.4 Promising Pipeline Molecules
4.4.1 Lumacaftor (VX809) – Vertex Pharmaceuticals
4.4.2 Ataluren (PTC124) – PTC Therapeutics
4.4.3 Aeroquin (levofloxacin) – Aptalis Pharma
4.4.4 Arikace (amikacin liposomal) – Insmed
4.4.5 Other Promising Molecules
4.5 Heat Map of Pipeline Products
4.6 Conclusion

5 Market Forecast to 2019
5.1 Geographical Markets
5.1.1 Global Markets
5.1.2 North America
5.1.3 Top Five EU Countries
5.2 Drivers and Barriers
5.2.1 Drivers
5.2.2 Barriers

6 Strategic Consolidations
6.1 Major Co-Development Deals
6.2 Major Licensing Deals

7 Appendix
7.1 References
7.1.1 Marketed Product Heat Map References
7.1.2 Pipeline Product Heat Map References
7.2 Market Definition
7.3 Abbreviations
7.4 Methodology
7.5 Coverage
7.6 Secondary Research
7.7 Therapeutic Landscape
7.8 Epidemiology-Based Forecasting
7.9 Market Size by Geography
7.10 Geographical Landscape
7.11 Pipeline Analysis
7.12 Competitive Landscape
7.12.1 Expert Panel Validation
7.13 Contact Us
7.14 Disclaimer

List of Tables


Table 1: Cystic Fibrosis Market, Global, Treatment Plan
Table 2: Cystic Fibrosis Market, Global, Pipeline, Preclinical
Table 3: Cystic Fibrosis Market, Global, Pipeline, Phase I
Table 4: Cystic Fibrosis Market, Global, Pipeline, Phase II
Table 5: Cystic Fibrosis Market, Global, Pipeline, Phase III
Table 6: Cystic Fibrosis Market, Global, Pipeline, Pre-Registration
Table 7: Cystic Fibrosis Market, Global, Pipeline, Undisclosed
Table 8: Cystic Fibrosis Market, Global, Market Forecast, 2012-2019
Table 9: Cystic Fibrosis Market, US, Market Forecast, 2012-2019
Table 10: Cystic Fibrosis Market, Canada, Market Forecast, 2012-2019
Table 11: Cystic Fibrosis Market, UK, Market Forecast, 2012-2019
Table 12: Cystic Fibrosis Market, France, Market Forecast, 2012-2019
Table 13: Cystic Fibrosis Market, Germany, Market Forecast, 2012-2019
Table 14: Cystic Fibrosis Market, Italy, Market Forecast, 2012-2019
Table 15: Cystic Fibrosis Market, Spain, Market Forecast, 2012-2019

List of Figures


Figure 1: Cystic Fibrosis Market, Global, Marketed, Heat Map
Figure 2: Cystic Fibrosis Market, Global, Pipeline Summary
Figure 3: Cystic Fibrosis Market, Global, Pipeline Mechanisms of Action
Figure 4: Cystic Fibrosis Market, Global, Clinical Trial Failure Rate
Figure 5: Cystic Fibrosis Market, Global, Pipeline Trial Duration
Figure 6: Cystic Fibrosis Market, Global, Pipeline, Trial Duration by Mechanism of Action
Figure 7: Cystic Fibrosis Market, Global, Pipeline Trial Size
Figure 8: Cystic Fibrosis Market, Global, Pipeline, Trial Size by Mechanism of Action
Figure 9: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Lumacaftor Forecast,
2015-2019
Figure 10: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Ataluren Forecast,
2016-2019
Figure 11: Cystic Fibrosis Market, Global, Pipeline Promising Pipeline Products, Aeroquin Forecast,
2014-2019
Figure 12: Cystic Fibrosis Market, Global, Pipeline, Promising Pipeline Products, Arikace Forecast,
2015-2019
Figure 13: Cystic Fibrosis Market, Global, Pipeline, Heat Map
Figure 14: Cystic Fibrosis Market, Global, Treatment Patterns, 2012–2019
Figure 15: Cystic Fibrosis Market, Global, Market Size, 2012–2019
Figure 16: Cystic Fibrosis Market, North America, Treatment Patterns, 2012–2019
Figure 17: Cystic Fibrosis Market, North America, Annual Cost of Treatment, 2012–2019
Figure 18: Cystic Fibrosis Market, North America, Market Size, 2012–2019
Figure 19: Cystic Fibrosis Market, Top Five EU Countries, Treatment Patterns, 2012–2019
Figure 20: Cystic Fibrosis Market, Top Five EU Countries, Annual Cost of Treatment, 2012–2019
Figure 21: Cystic Fibrosis Market, Top Five EU Countries, Market Size, 2012–2019
Figure 22: Cystic Fibrosis Market, Global, Major Co-developments by Region and Value, 2006–2013
Figure 23: Cystic Fibrosis Market, Global, Major Co-development Deals by Year, 2006–2013
Figure 24: Cystic Fibrosis Market, Global, Co-development Deals by Phase, 2006–2013
Figure 25: Cystic Fibrosis Market, Global, Licensing Deals by Region, 2006–2013
Figure 26: Cystic Fibrosis Market, Global, Licensing Deals by Year, 2006–2013
Figure 27: Cystic Fibrosis Market, Global, Licensing Deals by Phase, 2006–2013
Figure 28: Forecasting Model for Therapeutic Areas

Upcoming Reports:

Greece: market of aluminum doors and windows
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the aluminum doors and windows market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the aluminum doors and windows market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents...
Poland: styrene polymers market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the styrene polymers market in Poland and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the styrene polymers market in Poland, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an elaborate...
Oncology Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2012 - 2018
By - Transparency Market Research
Oncology is the study of Cancer. Oncology devices market consists of medical devices involved in diagnosing and treating the disease cancer. The Oncology devices market could be segmented into 2 major categories: by type and by applications. There are two types of Brachytherapy devices and the Endoscopic devices. The segmentation of the market as per the applications is as follows: external radiation beam therapy, Systemic radiation therapy, and the Brachytherapy  According to a report by the American Cancer Society 50% of men and 30% women are likely to develop...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

LG, Samsung to showcase home tech at IFA
Sep 2, 2014  
With this year’s IFA tech fair just round the corner, the participating companies are gearing up to showcase their latest gadgets. LG Electronics will be putting up an all-new set of appliances on display at the Internationale Funkausstellung (IFA) to be held from September 5 at Berlin. Televisions and wireless vacuum cleaners are two of its top devices on exhibit. LG’s...
Wine Consumption Prevents Cardiovascular Disease Only Among those who Exercise: Study
Sep 2, 2014  
Results from a latest study indicate that wine only prevents cardiovascular disease in people who engage in regular physical exercise. The study – In Vino Veritas – was presented by Prof. Milos Taborsky at the ESC Congress.  Prof. Taborsky, from the Czech Republic, said that this was the initial randomized trial that weighs both red and white wine against markers of...
New Drug Shows Early Promise against Heart Attacks and Strokes
Sep 1, 2014  
Sanofi and Regeneron Pharmaceuticals have been working on a new experimental drug that aims to lower cholesterol. Early tests have shown that the drug cuts down risks of heart attacks and strokes in clinical trials by half. The test report says that the results are not conclusive as the analysis was performed retrospectively. The study does provide the positive result that...
New Materials Creation Strategy
Sep 1, 2014  
Scientists always aim at theorizing about new compounds and materials; however after Researchers have made use of X-ray scattering in a process known as molecular beam epitaxy (MBE) to understand atom behavior as a kind of material called as layered oxides were getting formed. For computational predictions of new materials, the available observations were utilized for providing insights on...
Western Africa economies hit by Ebola travel ban
Aug 28, 2014  
With over 1,400 people dead due to the fatal Ebola outbreak in African countries, travel services have either banned or limited operations to the western region, severely hitting economies of the area. Budgetary resources are being utilized rapidly and economic growth has dropped by 4% as international projects and trips have been cancelled. Transport companies have cut off the region...